JP6552515B2 - ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用 - Google Patents

ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用 Download PDF

Info

Publication number
JP6552515B2
JP6552515B2 JP2016556270A JP2016556270A JP6552515B2 JP 6552515 B2 JP6552515 B2 JP 6552515B2 JP 2016556270 A JP2016556270 A JP 2016556270A JP 2016556270 A JP2016556270 A JP 2016556270A JP 6552515 B2 JP6552515 B2 JP 6552515B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
hpo
phosphate
biopterin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016556270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509623A (ja
JP2017509623A5 (enExample
Inventor
ペーター ショイラー
ペーター ショイラー
フランク テークトマイヤー
フランク テークトマイヤー
ラインハルト シンツェル
ラインハルト シンツェル
Original Assignee
ヴァソファーム ゲーエムベーハー
ヴァソファーム ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァソファーム ゲーエムベーハー, ヴァソファーム ゲーエムベーハー filed Critical ヴァソファーム ゲーエムベーハー
Publication of JP2017509623A publication Critical patent/JP2017509623A/ja
Publication of JP2017509623A5 publication Critical patent/JP2017509623A5/ja
Application granted granted Critical
Publication of JP6552515B2 publication Critical patent/JP6552515B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016556270A 2014-03-31 2015-03-30 ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用 Active JP6552515B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14162727.3A EP2926805B1 (en) 2014-03-31 2014-03-31 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EP14162727.3 2014-03-31
PCT/EP2015/056824 WO2015150294A1 (en) 2014-03-31 2015-03-30 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019123306A Division JP6879582B2 (ja) 2014-03-31 2019-07-02 ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用

Publications (3)

Publication Number Publication Date
JP2017509623A JP2017509623A (ja) 2017-04-06
JP2017509623A5 JP2017509623A5 (enExample) 2018-05-10
JP6552515B2 true JP6552515B2 (ja) 2019-07-31

Family

ID=50389975

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016556270A Active JP6552515B2 (ja) 2014-03-31 2015-03-30 ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用
JP2019123306A Active JP6879582B2 (ja) 2014-03-31 2019-07-02 ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用
JP2021072278A Active JP7178731B2 (ja) 2014-03-31 2021-04-22 ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019123306A Active JP6879582B2 (ja) 2014-03-31 2019-07-02 ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用
JP2021072278A Active JP7178731B2 (ja) 2014-03-31 2021-04-22 ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用

Country Status (28)

Country Link
US (7) US9895372B2 (enExample)
EP (2) EP2926805B1 (enExample)
JP (3) JP6552515B2 (enExample)
KR (1) KR102374500B1 (enExample)
CN (2) CN113521017A (enExample)
AU (2) AU2015239736B2 (enExample)
CA (1) CA2938267C (enExample)
CL (1) CL2016002463A1 (enExample)
CY (1) CY1117881T1 (enExample)
DK (1) DK2926805T3 (enExample)
ES (1) ES2586945T3 (enExample)
HR (1) HRP20160802T1 (enExample)
HU (1) HUE030221T2 (enExample)
IL (1) IL248090B (enExample)
MX (1) MX377919B (enExample)
MY (1) MY180844A (enExample)
PE (1) PE20161253A1 (enExample)
PH (1) PH12016501519B1 (enExample)
PL (1) PL2926805T3 (enExample)
PT (1) PT2926805T (enExample)
RS (1) RS54973B1 (enExample)
RU (1) RU2694368C2 (enExample)
SA (1) SA516371933B1 (enExample)
SG (1) SG11201606151SA (enExample)
SI (1) SI2926805T1 (enExample)
SM (1) SMT201600246B (enExample)
WO (1) WO2015150294A1 (enExample)
ZA (1) ZA201605271B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499532B2 (en) 2014-02-07 2016-11-22 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
JP2016168783A (ja) * 2015-03-13 2016-09-23 株式会社東芝 記録装置、記録方法、及び記録媒体
US12171766B2 (en) 2021-12-03 2024-12-24 Verinos Operations Gmbh Methods of treating patients suffering from brain injury and methods of increasing the value of the extended Glasgow Outcome Scale of patients suffering from brain injury
MX2020002271A (es) * 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP6565103B2 (ja) * 2017-09-06 2019-08-28 株式会社昭和冷凍プラント 香気成分含有水溶液を含む液状製品の製造方法
IL291565B1 (en) * 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
AU2021476139A1 (en) 2021-12-03 2024-05-09 Tibeay Biosciences B.V. Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury
TW202406555A (zh) 2022-05-06 2024-02-16 德商ｖｅｒｉＮＯＳ運營有限公司 治療患有與增加的麩胺酸水平相關的疾病狀況或病症的患者的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922713A (en) * 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
ATE201412T1 (de) 1997-10-06 2001-06-15 Ernst Werner Pteridinderivate als no synthase-hemmer
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
WO2005037286A1 (en) * 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
CA2545968C (en) * 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
US20080207624A1 (en) * 2004-05-11 2008-08-28 Osamu Sugita Therapeutic Agent for Bh4-Responsive Hyperphenylalaninemia
SE0401826D0 (sv) 2004-07-09 2004-07-09 Trimble Ab Method of preparing a winding for an n-phase motor
CN101132776A (zh) * 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
EP1669355A1 (en) * 2004-12-02 2006-06-14 Vasopharm Biotech GmbH Aminotetrahydropteridines and processes for manufacture thereof
KR20160065998A (ko) * 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
EP2140731A2 (de) 2007-04-24 2010-01-06 Osram Gesellschaft mit Beschränkter Haftung Schaltungsanordnung zur zündung und zum betrieb einer entladungslampe
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
CA2828685C (en) * 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
WO2013033194A1 (en) * 2011-08-30 2013-03-07 Fresenius Kabi Usa, Llc Levothyroxine formulations
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones

Also Published As

Publication number Publication date
IL248090B (en) 2019-10-31
CY1117881T1 (el) 2018-03-07
HRP20160802T1 (hr) 2016-08-12
MX377919B (es) 2025-03-10
US12458644B2 (en) 2025-11-04
PH12016501519A1 (en) 2017-02-06
MY180844A (en) 2020-12-10
US11717522B2 (en) 2023-08-08
US20260048056A1 (en) 2026-02-19
JP7178731B2 (ja) 2022-11-28
US20170296543A1 (en) 2017-10-19
JP2021105062A (ja) 2021-07-26
IL248090A0 (en) 2016-11-30
HK1213195A1 (en) 2016-06-30
EP2926805A1 (en) 2015-10-07
AU2015239736B2 (en) 2020-03-26
SG11201606151SA (en) 2016-08-30
US20220031703A9 (en) 2022-02-03
US10016431B2 (en) 2018-07-10
WO2015150294A1 (en) 2015-10-08
JP2019194227A (ja) 2019-11-07
RU2694368C2 (ru) 2019-07-12
PL2926805T3 (pl) 2016-12-30
CN106572976A (zh) 2017-04-19
JP6879582B2 (ja) 2021-06-02
SMT201600246B (it) 2016-08-31
US20230355630A1 (en) 2023-11-09
US9895372B2 (en) 2018-02-20
ES2586945T3 (es) 2016-10-19
AU2015239736A1 (en) 2016-08-11
SI2926805T1 (sl) 2016-09-30
RS54973B1 (sr) 2016-11-30
US20210137927A1 (en) 2021-05-13
US10493075B2 (en) 2019-12-03
KR102374500B1 (ko) 2022-03-15
US20170112836A1 (en) 2017-04-27
PT2926805T (pt) 2016-07-15
DK2926805T3 (en) 2016-07-25
CA2938267C (en) 2023-05-09
JP2017509623A (ja) 2017-04-06
CN113521017A (zh) 2021-10-22
CA2938267A1 (en) 2015-10-08
PE20161253A1 (es) 2016-11-13
US10925877B2 (en) 2021-02-23
RU2016141449A3 (enExample) 2018-12-14
BR112016020101A2 (enExample) 2017-07-15
HUE030221T2 (en) 2017-04-28
NZ722455A (en) 2022-03-25
AU2020203880B2 (en) 2022-03-31
CL2016002463A1 (es) 2017-01-27
RU2016141449A (ru) 2018-05-07
MX2016012784A (es) 2017-04-25
AU2020203880A1 (en) 2020-07-02
SA516371933B1 (ar) 2019-04-14
US20180289714A1 (en) 2018-10-11
BR112016020101A8 (pt) 2021-06-29
US20200046710A1 (en) 2020-02-13
KR20160138406A (ko) 2016-12-05
ZA201605271B (en) 2017-08-30
EP2926805B1 (en) 2016-05-18
EP3125864A1 (en) 2017-02-08
PH12016501519B1 (en) 2017-02-06

Similar Documents

Publication Publication Date Title
JP7178731B2 (ja) ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用
EP3856194A2 (en) Inhibitors of vap-1
JP6880058B2 (ja) シクロデキストリン−パノビノスタット付加物
TWI686197B (zh) 包含生物蝶呤衍生物之固體醫藥組合物及該等組合物之用途
HK40056723A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
HK1232799A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
HK1213195B (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
NZ722455B2 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
BR112016020101B1 (pt) Composição farmacêutica sólida, composição farmacêutica liofilizada, método para a preparação de uma composição farmacêutica liofilizada sólida, método para a preparação de uma solução injetável e uso da composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180320

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190702

R150 Certificate of patent or registration of utility model

Ref document number: 6552515

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533